Immunogen NASDAQ: IMGN
ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology.
Name | Immunogen |
Ticker | IMGN |
Exchange | NASDAQ |
Sector | Health Care |
Industry | Biopharmaceuticals |
Price
52W Low/High |
7.62
3.43 / 10.53 |
Momentum | Weak Down |
Market cap | 1.4 B |
1Y Total Return |
122.16%
Strong |
1Y Volatility |
75.20%
High Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology.
Details
Ticker | IMGN |
Name | Immunogen |
ISIN | US45253H1014 |
CUSIP | 45253H101 |
Exchange | NASDAQ |
Sector | Health Care |
Industry | Biopharmaceuticals |
Country | USA |
Currency | U.S. Dollar |
In Index(ices) | NASDAQ Biotechnology Index |
Share as of 4/14/21
Close Price | 7.62 |
52W Low/High | 3.43 / 10.53 |
Market cap | 1.4 B |
1Y Total Return |
122.16%
Strong |
1Y Volatility |
75.20%
High Risk |
Beta | 2.63 |
PE (trailing) | - |
12M Dividends | - |
Last Dividend Date | - |
Dividend Yield | - |
Fin. Strength
Net Profit Margin | -33.5% |
Cash from Op. / Cur. Liabilities | -0.64 |
Diluted Earnings / Share | -0.25 |
ROE | - |
ROIC | - |
Price / Revenue | 10.1 |
Price / Book | 15.0 |
Price / CF | -17.1 |
Current Ratio | 2.7 |
Cur.Liabilities / Tot.Liabilities | 0.5 |
Financial Leverage | 0.27 |
in Mils USD |
rolling-year up to December
|
||||||
---|---|---|---|---|---|---|---|
Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Revenue |
132
|
82
|
53
|
115
|
49
|
57
|
|
Gross Profit |
132
|
82
|
53
|
115
|
49
|
57
|
|
R&D |
115
|
115
|
174
|
140
|
141
|
129
|
|
EBITDA |
-42
|
-100
|
-161
|
-87
|
-148
|
-114
|
|
Operating Income |
-22
|
-92
|
-161
|
-59
|
-136
|
-103
|
|
Net Income exc. Extra |
-
|
-
|
-
|
-
|
-
|
-
|
|
per Share | |||||||
Diluted avg Shares |
176
|
148
|
140
|
98
|
87
|
87
|
|
EPS exc. Extra |
-0.25
|
-0.70
|
-1.21
|
-0.98
|
-1.81
|
-1.38
|
|
Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Total Assets |
355
|
235
|
295
|
295
|
199
|
252
|
|
Cash, Eq & Invt ShortTerm |
294
|
176
|
262
|
267
|
160
|
212
|
|
Total Current Assets |
324
|
209
|
279
|
276
|
176
|
223
|
|
Total Non-Current Assets |
31
|
26
|
17
|
18
|
23
|
28
|
|
Intangibles |
0
|
0
|
0
|
0
|
0
|
0
|
|
Total Liabilities |
266
|
311
|
284
|
313
|
352
|
268
|
|
Total Current Liabilities |
122
|
77
|
71
|
56
|
56
|
44
|
|
Long Term Debt |
143
|
234
|
214
|
257
|
296
|
224
|
|
Shareholder equity |
90
|
-76
|
11
|
-18
|
-153
|
-17
|
|
Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Cash from Operations |
-79
|
-88
|
-166
|
8
|
-143
|
-86
|
|
Depreciation |
2
|
4
|
7
|
6
|
6
|
5
|
|
Cash from Investing |
1
|
-1
|
-5
|
-1
|
-7
|
-10
|
|
Capex |
1
|
1
|
5
|
1
|
7
|
10
|
|
Cash from Financing |
196
|
3
|
167
|
101
|
97
|
202
|
|
Stock Issued |
196
|
3
|
167
|
102
|
0
|
8
|
|
Debt (LT) Issued |
0
|
0
|
0
|
0
|
97
|
0
|
|
Free Cash Flow |
-7
|
-112
|
-145
|
-97
|
-149
|
-94
|
|
Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Net Profit Margin |
-
|
-
|
-
|
-
|
-
|
-
|
|
NCFO / Op.Income |
-
|
-
|
-
|
-
|
-
|
-
|
|
Current Ratio |
2.7
|
2.7
|
3.9
|
5.0
|
3.2
|
5.1
|
|
Financial Leverage D/E |
0.27
|
-
|
0.19
|
-
|
-
|
-
|
|
Return on Capital Avg |
-
|
-
|
-
|
-
|
-
|
-
|
|
Return on Shareholder Equity |
-
|
-
|
-
|
-
|
-
|
-
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available